NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: jennie@carverwilde.com FOR IMMEDIATE RELEASE Abviris attracts almost 2M Euros to boost HPV cancer biomarker expansion Clinical study shows efficacy of novel lateral flow test AHRENSBURG, Germany (March 16, 2021) – Existing investors in…
Read More
NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: jennie@carverwilde.com FOR IMMEDIATE RELEASE Biotech innovator Abviris appoints new leader to drive business expansion Diagnostics industry expert Dr Roman Niedbal joins as CEO AHRENSBURG, Germany (December 16, 2020) –Abviris Deutschland GmbH has appointed…
Read More
NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: jennie@carverwilde.com FOR IMMEDIATE RELEASE ‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers Study shows rising antibody levels predict the course of cancer AHRENSBURG, Germany (November 10, 2020) – A potential breakthrough in…
Read More
Abviris Deutschland GmbH has been awarded “Pilot of the Year“ by the UK Diagnostics Summit 2019. This prestigious award was presented at the summit on 28 November 2019 in Manchester. High-ranking representatives of the National Health Service (NHS), diagnostics industry and the British IVD Association (BIVDA) honoured the results of a pilot study into the…
Read More
Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7. In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying…
Read More Abviris GmbH Obtains Almost 3 Million Euros in Pre-Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that…
Read More
